Hidradenitis suppurativa (HS) is a long-term skin condition that causes painful lumps, abscesses, and scars, often found under the skin in areas like armpits and groin. This study tests an experimental drug called lutikizumab for treating HS compared to a placebo, which is a harmless pill with no medicine. Participants will be split into two groups, with a 50% chance of getting the placebo.

The study has two phases. In the first phase, participants get weekly injections of either lutikizumab or placebo for 16 weeks. In the second phase, those who received lutikizumab continue with weekly or every-other-week injections for 36 weeks, and those who got the placebo switch to lutikizumab for 16 weeks, then continue for 20 more weeks.

Participation involves regular clinic or hospital visits for medical checks, blood tests, and answering questions. The study includes about 1280 participants worldwide. Eligibility requires having moderate to severe HS for at least 6 months and certain skin conditions. Those with infections like Hepatitis B, C, HIV, or tuberculosis cannot join.

• Study duration: up to 52 weeks.
• Regular hospital/clinic visits required.
• Potential higher treatment burden compared to usual care.